Company intelligence
Aignostics
AI-powered precision diagnostics for pathology
About Aignostics
Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.
Verified activity
Signals from Aignostics
2 published signals
Presence & Recognition
Aignostics is attending the ESPCongress starting this weekend with a team including Viktor Matyas, Julika Ribbat-Idel, Marius Teodorescu, Adi Ravia, and Aditya Jagannathan.
Reported by Aignostics
Research & Knowledge
Aignostics published a new preprint introducing LUCAID, a multimodal, agentic AI system for lung cancer pathology.
Reported by Aignostics